Literature DB >> 1270142

Solid-phase radioimmunoassay for antibodies to flavivirus structural and nonstructural proteins.

D W Trent, C L Harvey, A Qureshi, D LeStourgeon.   

Abstract

A micro-solid-phase radioimmunoassay (SPRIA) is described for quantitation of antibodies to purified flaviviruses as well as to the purified envelope glycoprotein and 80,000-molecular-weight viral nonstructural protein. Sera from mice experimentally infected with Saint Louis encephalitis (SLE) virus or from humans after a primary SLE virus infection reacted more specifically with the major viral envelope protein in the SPRIA test than with antigens conventionally used in the complement fixation (CF) and hemagglutination inhibition tests. A high degree of correlation (P is less than 0.05) was observed between SPRIA anti-immunoglobulin G binding values with the 80,000-molecular-weight nonstructural protein of SLE virus and antibody titers obtained by plaque reduction neutralization and CF with the nonstructural protein. In five of seven human sera in which CF antibody titers to the nonstructural protein were 4 or less, SPRIA testing revealed significant titers of IgG immunoglobulin reactive with this viral protein. The SPRIA test for antibodies reactive with group B togavirus nonstructural protein is as specific and sensitive as the plaque reduction neutralization test for titrating viral antibody in human and animal sera. Antibodies reactive with viral envelope proteins are broadly cross-reactive by the Spria technique, demonstrating both group- and complex-reactive antigenic determinants. The SPRIA test, using wells precoated with antigen, can be completed in 1 day, providing a rapid, highly sensitive test which can be adapted to use in testing a large number of sera.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1270142      PMCID: PMC420760          DOI: 10.1128/iai.13.5.1325-1333.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Rapid micro-radioimmunoassay for the measurement of antiviral antibody.

Authors:  J D Rosenthal; K Hayashi; A L Notkins
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

2.  Antigenic components of group A arbovirus virions.

Authors:  J M Dalrymple; S N Vogel; A Y Teramoto; P K Russell
Journal:  J Virol       Date:  1973-11       Impact factor: 5.103

3.  Antibody responses in rabbits to the group B arbovirus Kumjin: serologic activity of the fractionated immunoglobulins in homologous and heterologous reactions.

Authors:  E G Westaway
Journal:  J Immunol       Date:  1968-03       Impact factor: 5.422

4.  Specificity of IgM and IgG antibodies after challenge with antigenically related togaviruses.

Authors:  E G Westaway; A J Della-Porta; B M Reedman
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

5.  Radioimmune precipitation of group A arboviruses.

Authors:  J M Dalrymple; A Y Teramoto; R D Cardiff; P K Russell
Journal:  J Immunol       Date:  1972-09       Impact factor: 5.422

6.  Human immunoglobulin specificity after group B arbovirus infections.

Authors:  R M Scott; J M McCown; P K Russell
Journal:  Infect Immun       Date:  1972-09       Impact factor: 3.441

7.  Antibody responses in spider monkeys following single and double infections with group B arboviruses.

Authors:  G H Tignor; W H Price
Journal:  Am J Epidemiol       Date:  1971-10       Impact factor: 4.897

8.  Group B arbovirus structural and nonstructural antigens. II. Purification of Saint Louis encephalitis virus intracellular antigens.

Authors:  A A Qureshi; D W Trent
Journal:  Infect Immun       Date:  1973-12       Impact factor: 3.441

9.  Group B arbovirus structural and nonstructural antigens. I. Serological identification of Saint Louis encephalitis virus soluble antigens.

Authors:  A A Qureshi; D W Trent
Journal:  Infect Immun       Date:  1973-02       Impact factor: 3.441

10.  Human antibody to dengue soluble complement-fixing (SCF) antigens.

Authors:  W A Falkler; A R Diwan; S B Halstead
Journal:  J Immunol       Date:  1973-12       Impact factor: 5.422

View more
  8 in total

1.  Antigenicity of Japanese encephalitis virus envelope glycoprotein V3 (E) and its cyanogen bromide cleaved fragments examined by monoclonal antibodies and Western blotting.

Authors:  A K Srivastava; Y Aira; C Mori; Y Kobayashi; A Igarashi
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

2.  A novel method for increased yield of immunocompetent virus for vaccine production.

Authors:  A A Qureshi
Journal:  World J Microbiol Biotechnol       Date:  1991-09       Impact factor: 3.312

3.  Delayed-type hypersensitivity responses in mice infected with St. Louis encephalitis virus: kinetics of the response and effects of immunoregulatory agents.

Authors:  B W Hudson; K Wolff; J C DeMartini
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

4.  Topographical analysis of antigenic determinants on envelope glycoprotein V3 (E) of Japanese encephalitis virus, using monoclonal antibodies.

Authors:  J Kimura-Kuroda; K Yasui
Journal:  J Virol       Date:  1983-01       Impact factor: 5.103

5.  Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus.

Authors:  A Yasuda; J Kimura-Kuroda; M Ogimoto; M Miyamoto; T Sata; T Sato; C Takamura; T Kurata; A Kojima; K Yasui
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Authors:  Gregory D Gromowski; Nicholas D Barrett; Alan D T Barrett
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

7.  Evaluation of the solid-phase radioimmunoassay for diagnosis of St. Louis encephalitis infection in humans.

Authors:  K L Wolff; D J Muth; B W Hudson; D W Trent
Journal:  J Clin Microbiol       Date:  1981-08       Impact factor: 5.948

8.  Protease treatment and chemical crosslinking of a flavivirus: tick borne encephalitis virus.

Authors:  F X Heinz; C Kunz
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.